Immunomedics, Inc. (Nasdaq: IMMU) announced a 68% overall response rate in patients with immune thrombocytopenic purpura (ITP) treated with low ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE